Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

By Karissa Waddick • Oct. 11, 2022

Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

By Kim Ribbink • June 30, 2022

Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience

An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

By Kim Ribbink • June 16, 2022

Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

By Michael Gibney • May 17, 2022

Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

By Taren Grom • May 9, 2022

How OliX Pharmaceuticals is riding the RNAi wave

While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

By Karissa Waddick , Taren Grom • April 25, 2022